2026³â07¿ù09ÀÏthu
·Î±×ÀÎ | ȸ¿ø°¡ÀÔ
OFF
Æ®À§ÅÍ·Î º¸³»±â ½ÎÀÌ¿ùµå °ø°¨
±â»ç±ÛÈ®´ë ±â»ç±ÛÃà¼Ò ±â»ç½ºÅ©·¦ À̸ÞÀϹ®ÀÇ ÇÁ¸°Æ®Çϱâ
[02/18]´ëÇѰáÇÙ¹×È£Èí±âÇÐȸ Á¦13Â÷ õ½Ä¿¬±¸È¸¡¤COPD¿¬±¸È¸ °øµ¿½ÉÆ÷Áö¾ö
[ 2017³â 01¿ù 18ÀÏ 16½Ã 54ºÐ ]

´ëÇѰáÇÙ ¹× È£Èí±âÇÐȸ
Á¦13Â÷ õ½Ä¿¬±¸È¸ · COPD¿¬±¸È¸ °øµ¿ ½ÉÆ÷Áö¾ö

                  
• ÀÏ ÀÚ : 2017³â 2¿ù 18ÀÏ(Åä)
• Àå ¼Ò : °¡Å縯´ëÇб³ ¼­¿ï¼º¸ðº´¿ø ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°­´ç


13 : 30 ~ 13 : 50    µî        ·Ï                         
13 : 50 ~ 13 : 55    °³   ȸ   »ç                       Àα¤È£ õ½Ä¿¬±¸È¸Àå
13 : 55 ~ 14 : 00    Ãà       »ç       ±è¿µ±Õ ´ëÇѰáÇÙ ¹× È£Èí±âÇÐȸ ÀÌ»çÀå
                                                                »çȸ : ¹Ú¿ë¹ü

1ºÎ Phenotype in Airway Disease                                 ÁÂÀå : Àα¤È£ 
  
14 : 00 ~ 14 : 30 What Are the COPD Phenotypes/Endotypes Relevant for
                  Clinical Practice?    
                                ±èÀ¯ÀÏ(Àü³²ÀÇ´ë ³»°ú)
14 : 30 ~ 15 : 00 What Are the Asthma Phenotypes/Endotypes Relevant for
                  Clinical Practice?                        
                                ±è´ö°â(¼­¿ïÀÇ´ë ³»°ú)
15 : 00 ~ 15 : 30 Severe Asthma: Lessons Learned from Global Studies
                                Çã±Ô¿µ(°í·ÁÀÇ´ë ³»°ú)
15 : 30 ~ 15 : 50 Coffee Break

2ºÎ Update of Airway Disease                                   ÁÂÀå : ¾ÈÁßÇö

15 : 50 ~ 16 : 20   In What Patients Should I Use Fixed LABA-LAMA  
                    Combination in COPD ?    
                                ¾ö¼öÁ¤(µ¿¾ÆÀÇ´ë ³»°ú)
16 : 20 ~ 16 : 50   In What Patients Should I Use LAMA in Asthma ?      
                                ¹ÚÇýÀ±(¼º±Õ°üÀÇ´ë ³»°ú)
16 : 50 ~ 17 : 20   Update GOLD 2017                 
                                Á¤Áö¿¹(¿¬¼¼ÀÇ´ë ³»°ú)

17 : 20 ~ 17 : 30   Æó   ȸ   »ç                        ¾ÈÁßÇö COPD¿¬±¸È¸Àå 
 

µ¥Àϸ®¸Þµð dailymedi@dailymedi.com
À̱âÀÚÀÇ ´Ù¸¥´º½ºº¸±â
¹«ÅëÀåÀÔ±Ý Á¤º¸ÀÔ·Â ÀÔ±ÝÀÚ¸í ÀԱݿ¹Á¤ÀÏÀÚ
(ÀÔ±ÝÇÏ½Ç ÀÔ±ÝÀÚ¸í + ÀԱݿ¹Á¤ÀÏÀÚ¸¦ ÀÔ·ÂÇϼ¼¿ä)
[°ü·Ã´º½º]
- °ü·Ã´º½º°¡ ¾ø½À´Ï´Ù.
Æ®À§ÅÍ·Î º¸³»±â ½ÎÀÌ¿ùµå °ø°¨
±â»ç±ÛÈ®´ë ±â»ç±ÛÃà¼Ò ±â»ç½ºÅ©·¦ À̸ÞÀϹ®ÀÇ ÇÁ¸°Æ®Çϱâ
¸íÁöº´¿ø, ͺ À̰ÇÈñ ȸÀå ÁÖÄ¡ÀÇ À̰­¿ì ±³¼ö(»ï¼º¼­¿ïº´¿ø ÀçȰÀÇÇаú) ¿µÀÔ
´ëÀü¼º¸ðº´¿ø ±èµ¿±â¡¤À̵¿Ã¢ ±³¼ö, ´ëÇÑÀ̺ñÀÎÈİúÇÐȸ ÃÖ¿ì¼ö ±¸¿¬»ó¡¤ÃÖ¿ì¼ö Æ÷½ºÅÍ»ó
Á¶Àç¿ì ±³¼ö(°í´ë±¸·Îº´¿ø Á¤Çü¿Ü°ú), ´ëÇѰñÀýÇÐȸ ÃÖ´Ù³í¹®»ó
´ëÇÑÀÇ»çÇùȸ ºÎȸÀå ¹éÇö¿í¡¤Àǹ«ÀÌ»ç ¿Àµ¿È£¡¤Á¤º¸Åë½ÅÀÌ»ç À¯¼Ò¿µèâ
Çѱ¹Á¦¾à¹ÙÀÌ¿ÀÇùȸ ÀǾàǰ±¤°í½ÉÀÇÀ§¿øÈ¸ À§¿øÀå ±è¼ºÁø¡¤ºÎÀ§¿øÀå ÀÌÁØÈñ¡¤ÀåÃá°ï èâ
¹è±â¼ö ±³¼ö(¾ÆÁִ뺴¿ø ¼Ò¾ÆÃ»¼Ò³â°ú), Á¦100ȸ ¾î¸°À̳¯ ¿ÁÁ¶±ÙÁ¤ÈÆÀå
À̺´ÈÆ¡¤½ÉÀç¾Ó ±³¼öÆÀ(±æº´¿ø Á¤Çü¿Ü°ú), ´ëÇѰñÀýÇÐȸ ¿ÃÇØ ¿ì¼ö ±¸¿¬»ó
³²°¡Àº ±³¼ö(°í´ë±¸·Îº´¿ø °¡Á¤ÀÇÇаú), Çѱ¹¿©ÀÚÀÇ»çȸ Á¦4ȸ ÀþÀºÀÇÇÐÀÚ Çмú»ó
±¹¸³Áß¾ÓÀÇ·á¿ø Áß¾ÓÀÀ±ÞÀÇ·á¼¾ÅÍÀå ±è¼ºÁß(Á¶¼±´ëº´¿ø ÀÀ±ÞÀÇÇаú ±³¼ö)
ÃÖÁ¤¿õ ¿µ°æÀÇ·áÀç´Ü ÀüÁÖº´¿ø ÀÌ»çÀå, ¾Æµ¿º¸È£»ç¾÷ ±â±Ý 4000¸¸¿ø
±è¿µÁÖ ±³¼ö(ÀÌ´ë¸ñµ¿º´¿ø »êºÎÀΰú), Á¦13ȸ Çѵ¶¿©ÀÇ»çÇмú´ë»ó
¹ÚÂùÈì ±³¼ö(ÇѸ²´ëÃáõ¼º½Éº´¿ø À̺ñÀÎÈİú), ´ëÇÑÀ̺ñÀÎÈİúÇÐȸ Çмú»ó
Á¶¼öÁø ±³¼ö(ÇѸ²´ëµ¿Åº¼º½Éº´¿ø ½Å°æ°ú), Á¦26ȸ JWÁß¿ÜÇмú´ë»ó
¼­Á¤°Ç ¿¬¼¼¼­³»°ú ¿øÀå ÀåÀλó